fingolimod mylan
mylan ireland limited - fingolimod stutt og long-term - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1)orpatients með ört vaxandi alvarlega köstum skil heila-og mænusigg skilgreind af 2 eða meira að slökkva köst í eitt ár, og með 1 eða meira skuggaefna efla sár á heilanum segulÓmun eða mikil aukning í t2 sár álag eins og miðað við fyrri undanförnum segulÓmun.
fingolimod mylan
mylan ireland limited - fingolimod stutt og long-term - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
mitomycin medac duft og leysir fyrir þvagblöðrulausn 40 mg
medac gesellschaft für klinische spezialpräparate gmbh - mitomycinum inn - duft og leysir fyrir þvagblöðrulausn - 40 mg
risperdal consta stungulyfsstofn og leysir, forðadreifa 37,5 mg
janssen-cilag ab - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 37,5 mg
risperdal consta stungulyfsstofn og leysir, forðadreifa 25 mg
janssen-cilag ab - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 25 mg
bcg-medac duft og leysir fyrir þvagblöðrudreifu
medac gesellschaft für klinische spezialpräparate gmbh - bcg bacteria - duft og leysir fyrir þvagblöðrudreifu
eligard stungulyfsstofn og leysir, lausn 7,5 mg
recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 7,5 mg
eligard stungulyfsstofn og leysir, lausn 22,5 mg
recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 22,5 mg
ceftazidima normon (ceftazidime) stungulyfsstofn og leysir, lausn 1 g
laboratorios normon s.a. - ceftazidimum inn - stungulyfsstofn og leysir, lausn - 1 g
octaplex innrennslisstofn og leysir, lausn 1000 a.e.
octapharma ab - factor ii human; factor vii human; factor ix human; factor x human; protein c; protein s - innrennslisstofn og leysir, lausn - 1000 a.e.